02/23/2026
🚨 Big news for families navigating cerebral palsy 🚨
In 2025, Kidswell Bio—in partnership with Treehill Partners—announced the launch of Kidswell USA, a major step toward bringing innovative stem cell therapy for childhood cerebral palsy into the U.S. regulatory pathway.
For decades, treatment has focused on managing symptoms. Now, regenerative medicine is entering the conversation in a serious, structured way.
đź’ˇ What makes this different?
Kidswell’s research centers on SHED cells—stem cells derived from baby teeth—with neuroregenerative potential. Instead of simply replacing damaged tissue, the goal is to support the brain’s natural repair processes, reduce inflammation, and enhance neuroplasticity.
⚖️ Most importantly:
This effort signals a commitment to working through FDA channels and U.S. clinical trials—not unregulated offshore models. While the therapy isn’t available yet, families now have a reason for cautious optimism.
This could mark a meaningful shift from symptom management toward true regenerative possibilities.
Read more about what’s being developed, how it works, and what this means for families. 💙
https://www.cerebralpalsycenter.com/news/kidswell-launches-effort-to-bring-cerebral-palsy-stem-cell-therapy-to-us/